Phase II Trial of the MEK1 and MEK2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas)
studyName: Phase II Trial of the MEK1 and MEK2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas) dataStatus: Data Pending initiative: Other studyLeads: Dr. Brigitte Widemann studyStatus: Active diseaseFocus: Neurofibromatosis type 1 institutions: NCI Center for Cancer Research fundingAgency: Other manifestation: Plexiform Neurofibroma studyFileviewId: syn61259960 syn61259951 syn61259952 syn61259960 syn61259953
Drop files to upload
Phase II Trial of the MEK1 and MEK2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults with Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas) page is loading…